Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSMAddition: Pluvicto plus standard of care versus standard of care in PSMA-positive metastatic hormone-sensitive prostate cancer
2023-507970-42-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Mar 2021
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial in prostate cancer (PCa) comparing Pluvicto + standard of care with Standard of care (2 arms). Primary endpoint: Radiographic progression-free survival. Planned start Mar 2021; status: authorised.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2023-507970-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507970-42-00.